Senior Director, Health Economics and Outcomes Research, International

The role

You will lead the international HEOR strategy to secure patient access to products. This includes overseeing HTA submissions, value dossiers, and real-world evidence studies across multiple international markets.

What you will do

• Define and lead the international HEOR strategy
• Design and oversee non-interventional studies including registries and real-world evidence generation
• Lead early payer engagement with key HTA/payer bodies
• Collaborate with Market Access, Medical Affairs, and Commercial colleagues
• Provide health economic modeling and outcomes research expertise
• Manage external vendors, budgets, and contracts for HEOR studies

Required qualifications

• Graduate degree in health economics, epidemiology, health services research, or another research-focused public health field
• 9+ years of experience with an MSc/MPH, or 7+ years with a PhD, in HEOR or related fields
• Extensive experience leading HTA submissions and pricing negotiations across multiple international markets
• Direct experience engaging with HTA organizations such as NICE, CADTH, PBAC, HAS, IQWiG/G-BA, and ICER
• In-depth understanding of health economic modeling, patient-reported outcomes, statistics, and real-world evidence studies
• Ability to manage complex, multicultural, cross-functional teams and non-interventional study projects
• Project management abilities including contracting, budgeting, and vendor management
• Ability to influence senior stakeholders across medical, clinical, and commercial teams
• International mobility and willingness to travel internationally, approximately 10% of time

Nice to have

• PhD preferred

Benefits

• Market leading compensation
• Hybrid work model
• Career development through regular feedback, continuous education and professional development programs
• Financial rewards, peer-to-peer recognition, and growth opportunities

About the company

BridgeBio uses a moneyball for biotech approach, pooling projects and promising early-stage research from academia to reduce risk and unleash innovation. The company builds bridges to groundbreaking advancements in rare disease and develops medicines for patients with unmet needs.